



BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
--------------	------------	------------------	-------------------

Lupin to donate Yen 10 mn. for Japan's earthquake victims

Mumbai, 15th March, 2011: In the wake of the recent earthquake and tsunami that hit the coastal regions of Japan, affecting the lives of hundreds, Kyowa Yakuhin, Pharma major, Lupin Ltd's Japanese subsidiary, has announced that it would be donating Yen 10 million to the Japanese Red Cross, apart from donations in the form of medicines.

Commenting on the same, Mr. Vinod Dhawan, President, AAML & Business Development, Lupin Ltd. said, *"This is indeed an unprecedented event and our heart goes out to all those afflicted. The human loss that this calamity has caused is truly shocking and we are deeply saddened by the extent of the damage caused by the disaster and have taken a small step forward to extend our support and solidarity with the Japanese people. We offer our full support and any help that authorities might require in relief operations and we will do as much as we can to help the disaster victims."*

Lupin's subsidiary Kyowa Yakuhin, located in Sanda, Japan has remained unaffected and all 355 personnel are safe. Kyowa is one of the largest generic players in the neurology segment and is amongst the fastest growing generic pharmaceutical companies in Japan today.

About Lupin Limited

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company today has significant presence in Cardiovasculars (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs not to mention global leadership positions in the Anti-TB and Cephalosporins. The Company's R&D endeavors have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals.

Today, Lupin has emerged as the 5th largest and the fastest growing Top 5 company in the U.S (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing, top 5 pharmaceutical players in India (ORG IMS) and the fastest growing, top 10 Generic players in Japan and South Africa. (IMS)

For the financial year ended March 2010, Lupin's Consolidated Sales and Profit after Tax were Rs.47,678 million and Rs. 6,816 million respectively.

For further information or queries please contact -

Shamsher Gorawara
Head - Corporate Communications
Lupin Limited:
Ph: +91 98 20 338 555
Email: shamshergorawara@lupinpharma.com

or

Sonia Mansata
Text 100 Public Relations
Ph: +91 98 20 11 2481
Email: sonia.mansata@text100.co.in